Detection of clinically relevant early genomic lesions in B-cell malignancies from circulating tumour DNA using a single hybridisation-based next generation sequencing assay

Br J Haematol. 2018 Oct;183(1):146-149. doi: 10.1111/bjh.14919. Epub 2017 Sep 7.

Authors

Piers A Blombery¹, Georgina L Ryland¹, John Markham¹, Jerick Guinto¹, Meaghan Wall^{2

3

4}, Michelle McBean¹, Kate Jones¹, Ella R Thompson^{1

3}, Daniel L Cameron⁵, Anthony T Papenfuss^{1

3

5}, Miles H Prince^{1

3}, Michael Dickinson^{1

3}, David Alan Westerman^{1

3}

Affiliations

¹ Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.
² Victorian Cancer Cytogenetics Service, Melbourne, Vic., Australia.
³ Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Vic., Australia.
⁴ St Vincent's Institute of Medical Research, Fitzroy, Vic., Australia.
⁵ Walter and Eliza Hall Institute of Medical Research, Melbourne, Vic., Australia.

PMID: 28880377
DOI: 10.1111/bjh.14919

No abstract available

Keywords: ctDNA; lymphoma; myeloma; next generation sequencing.

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
B-Lymphocytes / pathology
Burkitt Lymphoma / diagnosis
Burkitt Lymphoma / genetics
Circulating Tumor DNA / genetics*
Female
Genomics
High-Throughput Nucleotide Sequencing / methods*
Humans
Lymphoproliferative Disorders / diagnosis*
Lymphoproliferative Disorders / genetics
Male
Multiple Myeloma / diagnosis
Multiple Myeloma / genetics
Nucleic Acid Hybridization

Substances

Circulating Tumor DNA